Astrazeneca (AZN) Debt to Equity (2006 - 2026)
Astrazeneca (AZN) debt to equity from Mar 31, 2006 to Mar 31, 2026. The current Astrazeneca (AZN) debt to equity is 71.66%. You can export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Debt to Equity
Debt to Equity
Annual Debt to Equity change of Astrazeneca (AZN)
| Year | Debt to Equity | Change |
|---|---|---|
| 2025 | 61.03% | -17.34% |
| 2024 | 73.83% | +0.97% |
| 2023 | 73.12% | -7.07% |
| 2022 | 78.69% | +0.69% |
| 2021 | 78.15% | -40.10% |
| 2020 | 130.46% | -6.05% |
| 2019 | 138.85% | -9.42% |
| 2018 | 153.30% | +28.79% |
| 2017 | 119.03% | +5.19% |
| 2016 | 113.15% | +38.99% |
| 2015 | 81.41% | +47.36% |
| 2014 | 55.25% | +23.65% |
| 2013 | 44.68% | +2.86% |
| 2012 | 43.43% | +8.24% |
| 2011 | 40.13% | -2.92% |
| 2010 | 41.33% | -24.47% |
| 2009 | 54.73% | -26.50% |
| 2008 | 74.46% | -27.40% |
| 2007 | 102.56% | +1183.36% |
| 2006 | 7.99% | N/A |
Comparison Astrazeneca (AZN) debt to equity with competitors
Astrazeneca (AZN) debt to equity is 71.66%.
| Ticker | Name | Debt to Equity | Upside |
|---|---|---|---|
| SNY | Sanofi | 27.50% | -61.63% |
| BIIB | Biogen Inc | 33.72% | -52.95% |
| JNJ | Johnson & Johnson | 67.73% | -5.48% |
| PFE | Pfizer Inc | 71.50% | -0.21% |
| NVO | Novo Nordisk | 72.09% | +0.60% |
| GILD | Gilead Sciences Inc | 94.30% | +31.59% |
| GSK | GSK Plc | 106.74% | +48.96% |
| MRK | Merck & Co Inc | 107.06% | +49.40% |
| NVS | Novartis AG | 122.03% | +70.30% |
| LLY | Lilly(Eli) & Company | 139.02% | +94.00% |
| MDCX | MDCorp | 176.75% | +146.65% |
| MDCXW | Medicus Pharma Ltd warrant | 176.75% | +146.65% |
| GRFS | Grifols SA | 177.15% | +147.22% |
| BMY | Bristol-Myers Squibb Company | 219.95% | +206.95% |
| AMGN | AMGEN Inc | 623.75% | +770.46% |
| OGN | Organon & Company | 948.95% | +1224.27% |